Stanford's James Zou targets $1B valuation for AI physiology startup backed by Nature-published research and FDA-cleared

This article was published on April 25, 2026 Summary: Stanford professor James Zou is reportedly raising approximately $100 million at a valuation targeting $1 billion for a startup called Human Intelligence that applies AI to research on the human body, according to Bloomberg. Zou’s research includes an FDA-cleared cardiac AI (EchoNet), a Nature-published Virtual Lab that designed novel nanobodies, and a Virtual Biotech multi-agent framework that annotated 56,000 clinical trials. The deal specifics are single-source, but the researcher’s credentials are among the strongest in AI-biology, and the funding environment, $11 billion into AI drug discovery in Q1 2026 alone, is historically accommodating. James Zou has spent the past decade building AI systems that do science. His Virtual Lab, published in Nature in July 2025, assembled a team of large language model agents led by an AI principal investigator that designed 92 novel nanobody binders against SARS-CoV-2 variants, two of which showed improved binding in experimental validation. His Virtual Biotech, posted as a preprint in February 2026, created a multi-agent framework mimicking a pharmaceutical company’s hierarchy with 11 sp

Apr 25, 2026 → Apr 25, 2026